A
Actithera develops next-generation radioligand therapies by linking radioactive isotopes to precisely designed molecules for targeted cancer treatment. Their proprietary chemistry ensures prolonged tumor retention and minimized off-target effects on healthy tissues. This approach aims to deliver effective treatment with fewer cycles, enhancing patient quality of life.
Updated 2 months ago
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Actithera develops next-generation radioligand therapies by linking radioactive isotopes to precisely designed molecules for targeted cancer treatment. Their proprietary chemistry ensures prolonged tumor retention and minimized off-target effects on healthy tissues. This approach aims to deliver effective treatment with fewer cycles, enhancing patient quality of life.